IVL posts strong Q3 2026 profit — with management upbeat on 2027. Indorama Ventures posted a 2.17 billion Baht net profit in Q3 2026, reversing a loss a year earlier, while EBITDA jumped 65% to 13.72 billion Baht. Management also signalled support for consistent dividends and expressed a positive outlook for 2027, as cost cuts, portfolio optimisation and deleveraging continue to strengthen the business. #IVL# #IndoramaVentures# #Earnings# #stockmarket# #Thailand#

Shockwave IVL and innovation continue to go hand in hand as we deliver new advancements to address severe, complex calcium meeting physician and patient needs alike. Thank you, Dr. @rwyeh for presenting the FORWARD CAD 30-day results at #TCT2026# today. FORWARD CAD met its performance goals, demonstrating high technical success (93.6%) and a high rate of freedom from MACE through 30 days (93.4%) in a highly stenotic lesion cohort. These data from the prospective, multicenter, single-arm, IDE study of the Shockwave Javelin #CoronaryIVL# catheter show how the robust #ShockwaveIVL# portfolio is expanding beyond balloon-based therapies for the coronaries. Read the press release: CAUTION - Investigational device. Limited by US law to investigational use.

The Shockwave IVL Experience Center is in full swing at CIRSE 2026 📍 Attend the Fem-Pop session at 11:00 today, register here: Over the past few days at the Shockwave IVL Experience Center, our faculty have been sharing practical insights, hands-on learnings on the treatment of complex peripheral artery disease and diving into expert-led discussions on procedural treatment with #ShockwaveIVL#. #CIRSE2026# #ShockwaveIVLExperienceCenter# #ShockwaveIVL# #BTK# #FemPop# US Rx only. Safety Info:  Product availability may vary by country

The largest real-world data set yet for Shockwave Coronary IVL, presented at #TCT2026#.⚡ The CathPCI Registry data set analyzed more than 250,000 #ShockwaveCoronaryIVL# outcomes, offering a powerful look at its use in everyday practice, including highly complex #ComplexPCI# cases with 79.3% high complexity lesions and 55.8% multivessel disease. The findings support consistent, predictable coronary performance in real-world practice. Thank you to Dr. @PrakritiGaba for presenting these important findings and bringing insights from this extensive data set to the field. US Rx only. Safety info: Product availability may vary by country.